Interferon in the treatment of AIDS-associated Kaposi's sarcoma: the American experience.
This report is intended to summarize the use of Interferon in the treatment of Kaposi's sarcoma (KS) associated with AIDS. The review is basically focused on the trials in the United States, which resulted in approval by the Food & Drug Administration (FDA) of the use of recombinant interferon alpha for the treatment of Kaposi's sarcoma.
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
B
B
Safai
M
M
Bason
R
R
Friedman-Birnbaum
L
L
Nisce
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D002986:Clinical Trials as Topic; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use; D007372:Interferons / Q000009:adverse effects / Q000627:therapeutic use*; D009367:Neoplasm Staging; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D016019:Survival Analysis
D007370:Interferon Type I; D007372:Interferons